Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Aim: Treatment for opioid use disorders has recently evolved to include long-acting injectable and implantable formulations of medications for opioid use disorder (MOUD). Incorporating patient preferences into treatment for substance use disorders is associated with increased motivation and treatment satisfaction. This study sought to assess treatment preferences for long-acting injectable and implantable MOUD as compared to short-acting formulations among individuals with OUD. Methods: We conducted qualitative, semi-structured telephone interviews with forty adults recruited from across the United States through Craigslist advertisements and flyers posted in treatment programs. Eligible participants scored a two or greater on the heroin or opioid pain reliever sections of the Tobacco, Alcohol, Prescription Medications, and Other Substances (TAPS) Tool, indicative of a past-year OUD. Interviews were transcribed, coded, and thematically analyzed. Results: Twenty-four participants (60%) currently or previously had been prescribed MOUD. Sixteen participants (40%) expressed general opposition to MOUD, citing concerns that MOUD is purely financial gain for pharmaceutical companies and/or a “band aid” solution replacing one drug with another, rather than a path to abstinence. Some participants expressed personal preference for long-acting injectable (n = 16/40: 40%) and implantable formulations (n = 12/40: 30%) over short-acting formulations. About half of the participants were not willing to use injectables (n = 19/40: 48%) or implantables (n = 22/40: 55%), preferring short-acting formulations. Mixed evaluations of long- and short-acting MOUD focused on considerations of medication-related beliefs (privacy, concern over an embedded foreign body), the medication-related burden (convenience, provision of structure and support, medication administration, potential side effects), and medication-taking practices (potential for non-prescribed use, control over dosage, and duration of treatment). Conclusions: Though many participants personally prefer short-acting to long-acting MOUD, some were open to including long-acting formulations in the range of options for those with OUD. Participants felt long-acting formulations may reduce medication-related burden and the risk of diversion. Conversely, participants expressed concern about invasive administration and loss of control over their treatment. Results suggest support for expanded access to a variety of formulations of MOUD. The use of shared decision making may also help patients select the formulation best aligned with their experiences, values, and treatment goals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saturation in qualitative research: exploring its conceptualization and operationalization
Saunders, B., Sim, J., Kingstone, T., Baker, S., Waterfield, J., Bartlam, B., Burroughs, H., & Jinks, C. (2018) · Quality & Quantity · doi:10.1007/s11135-017-0574-8 · Cited by 12,033 · cited 1×
“As 12 to 20 interviews are generally suggested to achieve thematic saturation (Guest, Bunce, & Johnson, 2006), we planned to recruit up to 40 participants, continuing interviews until thematic saturation was reached and no new themes were emerging (Saunders et al., 2018).”
BackgroundShared decision making: A model for clinical practice
Elwyn, G., Frosch, D., Thomson, R., Joseph-Williams, N., Lloyd, A., Kinnersley, P., Cording, E., Tomson, D., Dodd, C., Rollnick, S., et al. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2077-6 · Cited by 4,405 · cited 2×
“, 2016; Legare & Witteman, 2013), is one way of incorporating individual patient preferences, values, and goals into the treatment plan (Elwyn et al., 2012; Friedrichs et al., 2016; Marshall et al., 2018).”
BackgroundSordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816 · cited 5×
“As both short- and long-acting formulations have been rigorously studied (Mattick et al., 2014; Nielsen et al., 2016; Sordo et al., 2017), the decision for one formulation over another is largely preference sensitive, a choice that depends on patients’ preferences and their individual values…”
BackgroundInfluentialMeta‐analysis of cue‐reactivity in addiction research
Carter, B. L., & Tiffany, S. T. (1999) · Addiction · doi:10.1046/j.1360-0443.1999.9433273.x · Cited by 1,638 · cited 1×
“Cue reactivity to drug-related stimuli, including needles or injecting paraphernalia, has long been associated with relapse (Carter & Tiffany, 1999; Childress et al., 1993; Namba, Tomek, Olive, Beckmann, & Gipson, 2018).”
BackgroundOpioid-induced Hyperalgesia: A Qualitative Systematic Review
Angst, M. S., & Clark, J. D. (2006) · Anesthesiology · doi:10.1097/00000542-200603000-00025 · Cited by 1,188
Opioid Epidemic in the United States
Manchikanti, L. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/es9 · Cited by 1,180
Joosten, E. A. G., DeFuentes-Merillas, L., de Weert, G. H., Sensky, T., van der Staak, C. P. F., & de Jong, C. A. J. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000126073 · Cited by 1,135 · cited 1×
“The consideration of patient preference may be particularly important when treating chronic illnesses, like OUD, when patients are engaged in long-term treatments (Fallah, 2015; Friedrichs, Spies, Harter, & Buchholz, 2016; Joosten et al., 2008).”
BackgroundLégaré, F., & Witteman, H. O. (2013) · Health Affairs · doi:10.1377/hlthaff.2012.1078 · Cited by 783
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Management of opioid use disorder in the USA: present status and future directions
Blanco, C., & Volkow, N. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33078-2 · Cited by 407
Development of a Cascade of Care for responding to the opioid epidemic.
Williams, A. R., Nunes, E. V., Bisaga, A., Levin, F. R., & Olfson, M. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1546862 · Cited by 332
Morgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.07.001 · Cited by 332
McNeely, J., Wu, L.-T., Subramaniam, G., Sharma, G., Cathers, L. A., Svikis, D., Sleiter, L., Russell, L., Nordeck, C., Sharma, A., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0317 · Cited by 320
Syed, Y. Y., & Keating, G. M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0110-x · Cited by 72
Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management
Kenney, S. R., Anderson, B. J., Bailey, G. L., & Stein, M. D. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.08.011 · Cited by 40 · cited 3×
“, 2019) or were treatment seeking (Kenney et al., 2018), almost half of participants in the current study had never received MOUD.”
BackgroundResult
Cited by
Morgan, J. R., Walley, A. Y., Murphy, S. M., Chatterjee, A., Hadland, S. E., Barocas, J., Linas, B. P., & Assoumou, S. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108764 · Cited by 67
Morgan, J. R., Quinn, E. K., Chaisson, C. E., Ciemins, E., Stempniewicz, N., White, L. F., Linas, B. P., Walley, A. Y., & LaRochelle, M. R. (2022) · Medical Care · doi:10.1097/mlr.0000000000001689 · Cited by 30
Socías, M. E., & Nolan, S. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000697 · Cited by 2
“Un 16 acceptability and uptake of these novel medications in different settings.(14,15) Given current higher costs of extended-release buprenorphine compared to available oral formulations, this information will be key for health care programming, and allow for targeting of those who might benefit the most from these…”
Background
Metadata
- Authors
- Saunders, E. C., Moore, S. K., Walsh, O., Metcalf, S. A., Budney, A. J., Scherer, E., & Marsch, L. A.
- Venue
- Journal of Substance Abuse Treatment
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 111
- Pages
- 54-66
- ISSN
- 0740-5472 (ISSN-L)
- OpenAlex
- W3000990449
- Cited by
- 51
- References
- 15
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.